MCCOURT Thomas A 4

What Happened
Thomas A. McCourt, CEO of Ironwood Pharmaceuticals (IRWD), received a grant of 409,836 restricted stock units (RSUs) on 2026-03-10. The grant price is reported as $0.00 because this is an award (not a purchase); the RSUs will convert to shares of Class A common stock as they vest. The Form 4 was filed on 2026-03-12.

Key Details

• Transaction date: 2026-03-10; transaction type: Award/Grant (code A).
• Shares/units granted: 409,836 RSUs; acquisition price reported: $0.00.
• Vesting: Per footnote, the award vests 33.33% of the shares on each approximately annual anniversary of the grant (three installments).
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: Form 4 filed 2026-03-12 (within the normal two-business-day reporting window).

Context
RSU grants are a form of compensation that vest over time; they do not represent an immediate cash purchase or sale. For investors, such awards are common for executives and primarily reflect compensation arrangements rather than a direct insider buy/sell signal. Watch future Form 4s for vesting-related share issuances or any subsequent sales.